Tedizolid: new data and experiences for clinical practice.

Autores de IIS La Fe

• Miguel Salavert Lletí

  Autor

• Víctor García Bustos

  Autor

• Marta Dafne Cabañero Navalón

  Autor

Participantes ajenos a IIS La Fe

• Morata Ruiz, L

Grupos

• Infección Grave

Abstract

The most relevant information on the clinical uses of tedizolid from studies published in the last 18 months is presented in this brief review. The most important data indicate better tolerance and safety profile of long-term therapeutic regimes in off-label indications, such as osteoarticular infections and those caused by mycobacteria. Its lower risk of hazardous interactions compared to linezolid should be emphasized. Furthermore, tedizolid in its combination with rifampicin shows a more favourable way of acting as demonstrated in vitro and in vivo studies. A recent trial also opens the door for its potential use in nosocomial pneumonia caused by Gram-positive bacteria.

Keywords

• Tedizolid phosphate; Gram-positive; osteoarticular infections; pneumonia; safety